Skip to main content

Research Repository

Advanced Search

Outputs (23)

Investigation of the regulatory role of CBX2 in breast cancer via in silico transcriptomic analysis and in vitro cistromic analysis (2021)
Thesis
Kalsi, S. C. Investigation of the regulatory role of CBX2 in breast cancer via in silico transcriptomic analysis and in vitro cistromic analysis. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4224331

Chromobox 2 (CBX2) is a component of Polycomb repressive protein complex 1 (PRC1), which is an epigenetic regulatory complex that downregulates the expression of target genes. CBX2 has been linked to cancer progression and development in several canc... Read More about Investigation of the regulatory role of CBX2 in breast cancer via in silico transcriptomic analysis and in vitro cistromic analysis.

Investigating the role of CBX2 in models of triple negative breast cancer (2019)
Thesis
Warren, C. Investigating the role of CBX2 in models of triple negative breast cancer. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4222872

Breast cancer accounts for around 11,500 deaths per year in the UK in women. There are several subtypes of breast cancer including triple negative breast cancer (TNBC) which is categorised by a lack of oestrogen, progesterone and human epidermal grow... Read More about Investigating the role of CBX2 in models of triple negative breast cancer.

Investigating the role of CBX2 in ER- positive breast cancer (2019)
Thesis
Waters, E. J. Investigating the role of CBX2 in ER- positive breast cancer. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4222704

Breast cancer is the most common form of cancer in women, with oestrogen receptor (ER) positive breast cancers being the most common subtype. Although there are targeted endocrine therapies for this receptor, resistance mechanisms mean that they are... Read More about Investigating the role of CBX2 in ER- positive breast cancer.

The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer (2019)
Journal Article
Jones, D., Wilson, L., Thomas, H., Gaughan, L., & Wade, M. A. (2019). The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer. Cancers, 11(8), Article 1122. https://doi.org/10.3390/cancers11081122

Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine therapy but retain canonical receptor signalling in the presence of selective ER antagonists. Numerous co-regulatory proteins, including enzymes that modulate the chr... Read More about The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer.

The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart (2019)
Journal Article
Onwuli, D. O., Samuel, S., Sfyri, P., Welham, K., Goddard, M., Abu-Omar, Y., Loubani, M., Rivero, F., Matsakas, A., Benoit, D. M., Wade, M., Greenman, J., & Beltran-Alvarez, P. (2019). The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart. International journal of cardiology, 282, 76-80. https://doi.org/10.1016/j.ijcard.2019.01.102

Background
The inhibitory subunit of cardiac troponin (cTnI) is a gold standard cardiac biomarker and also an essential protein in cardiomyocyte excitation-contraction coupling. The interactions of cTnI with other proteins are fine-tuned by post-tra... Read More about The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart.

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition (2015)
Journal Article
Middleton, F. K., Patterson, M. J., Elstob, C. J., Fordham, S., Herriott, A., Wade, M. A., McCormick, A., Edmondson, R., May, F. E., Allan, J. M., Pollard, J. R., & Curtin, N. J. (2015). Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget, 6(32), 32396-32409. https://doi.org/10.18632/oncotarget.6136

ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alon... Read More about Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer (2015)
Journal Article
Jones, D., Wade, M., Nakjang, S., Chaytor, L., Grey, J., Robson, C. N., & Gaughan, L. (2015). FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget, 6(30), 29782-29794. https://doi.org/10.18632/oncotarget.4927

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression... Read More about FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy (2015)
Journal Article
O’Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., Guo, W., Cork, D., Davies, B. R., Wedge, S. R., Robson, C. N., & Gaughan, L. (2015). Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget, 6(28), 26029-26040. https://doi.org/10.18632/oncotarget.4347

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection o... Read More about Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

Does radiation-induced c-MYC amplification initiate breast oncogenesis? (2015)
Journal Article
Wade, M. A., May, F. E., Onel, K., & Allan, J. M. (2016). Does radiation-induced c-MYC amplification initiate breast oncogenesis?. Molecular and Cellular Oncology, 3(1), Article e1010950. https://doi.org/10.1080/23723556.2015.1010950

© 2016 Taylor and Francis Group, LLC. The MYC (v-myc avian myelocytomatosis viral oncogene homolog; c-MYC) locus on chromosome 8q is susceptible to high-level amplification following exposure of human breast cells to ionizing radiation, and c-MYC amp... Read More about Does radiation-induced c-MYC amplification initiate breast oncogenesis?.

c-MYC is a radiosensitive locus in human breast cells (2014)
Journal Article
Wade, M. A., Sunter, N. J., Fordham, S. E., Long, A., Masic, D., Russell, L. J., Harrison, C. J., Rand, V., Elstob, C., Bown, N., Rowe, D., Lowe, C., Cuthbert, G., Bennett, S., Crosier, S., Bacon, C. M., Onel, K., Scott, K., Scott, D., Travis, L. B., …Allan, J. M. (2015). c-MYC is a radiosensitive locus in human breast cells. Oncogene, 34(38), 4985-4994. https://doi.org/10.1038/onc.2014.427

Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is... Read More about c-MYC is a radiosensitive locus in human breast cells.